Last updated on February 2019

Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)


Brief description of study

This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of this study is to compare the effect of quizartinib versus placebo (administered with standard induction and consolidation chemotherapy, then administered as maintenance therapy for up to 12 cycles) on event-free survival in subjects with FLT3-internal tandem duplication (ITD) positive AML.

Clinical Study Identifier: NCT02668653

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Prince of Wales Hospital
Shatin, Hong Kong
  Connect »

Study Coordinator

Queen Mary Hospital
Hong Kong, Hong Kong
5.77miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.